Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study-Reference-Cited by-同舟云学术

Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study

Published:2020-04-12 Issue:5 Volume:16 Page:750-758
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Lopes Alves Isadora¹,Collij Lyduine E.¹,Altomare Daniele²³,Frisoni Giovanni B.²³,Saint‐Aubert Laure⁴⁵,Payoux Pierre⁴⁵,Kivipelto Miia⁶,Jessen Frank⁷,Drzezga Alexander⁷,Leeuwis Annebet⁸,Wink Alle Meije¹,Visser Pieter Jelle⁸,Berckel Bart N.M.¹,Scheltens Philip⁸,Gray Katherine R.⁹,Wolz Robin⁹,Stephens Andrew¹⁰,Gismondi Rossella¹⁰,Buckely Christopher¹¹,Gispert Juan Domingo¹²¹³¹⁴,Schmidt Mark¹⁵,Ford Lisa¹⁶,Ritchie Craig¹⁷,Farrar Gill¹¹,Barkhof Frederik¹¹⁸,Molinuevo José Luis¹²¹⁴¹⁹,

Affiliation:

1. Department of Radiology and Nuclear Medicine Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam the Netherlands

2. Laboratory of Neuroimaging of Aging (LANVIE) University of Geneva Geneva Switzerland

3. Memory Clinic University Hospital of Geneva Geneva Switzerland

4. Department of Nuclear Medicine Imaging Pole Toulouse, University Hospital Toulouse France

5. Toulouse NeuroImaging Center Université de Toulouse, Inserm, UPS Toulouse France

6. Department of Geriatric Medicine Karolinska University Hospital Huddinge Stockholm Sweden

7. Department of Nuclear Medicine University of Cologne Cologne Germany

8. Department of Neurology, Amsterdam UMC Vrije Universiteit Amsterdam Alzheimercenter Amsterdam the Netherlands

9. IXICO Plc London United Kingdom

10. Life Molecular Imaging GmbH Berlin Germany

11. GE Healthcare Life Sciences Amersham United Kingdom

12. Barcelona β Brain Research Center Barcelona Spain

13. Centro de Investigación Biomédica en Red de Bioingeniería Biomateriales y Nanomedicina (CIBER‐BBN) Madrid Spain

14. Universitat Pompeu Fabra Barcelona Spain

15. Janssen Pharmaceutica NV Beerse Belgium

16. Janssen Pharmaceutica RND Titusville New Jersey USA

17. Centre for Clinical Brain Sciences University of Edinburgh Edinburgh United Kingdom

18. Centre for Medical Image Computing Medical Physics and Biomedical Engineering, UCL London United Kingdom

19. Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) Madrid Spain

Funder

European Union's Horizon 2020

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12069

Reference45 articles.

1. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

2. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

3. Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

4. Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

5. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elevated cerebral blood flow proxy with increased beta-amyloid burden in Alzheimer’s disease preclinical phase evaluated by dual-phase 18F-florbetaben positron emission tomography;Scientific Reports;2024-08-09

2. Digital remote assessment of speech acoustics in cognitively unimpaired adults: feasibility, reliability and associations with amyloid pathology;Alzheimer's Research & Therapy;2024-08-01

3. Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity;Neurology;2024-07-09

4. Combined quantitative amyloid-β PET and structural MRI features improve Alzheimer’s Disease classification in random forest model - A multicenter study;Academic Radiology;2024-07

5. Amyloid-PET imaging predicts functional decline in clinically normal individuals;Alzheimer's Research & Therapy;2024-06-17